Olmesartan

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In

Retrieved on: 
Wednesday, June 6, 2018
Alcohols, Imidazoles, Olmesartan, Tetrazoles, Gastrointestinal tract disorders, Chemistry, Daiichi Sankyo, Medicine, Enteropathy, Anuria, Economy of Japan

These cases are related to olmesartan products (Benicar, Benicar HCT, Azor and Tribenzor) and allegations that such products caused sprue-like enteropathy and other severe gastro-intestinal symptoms.

Key Points: 
  • These cases are related to olmesartan products (Benicar, Benicar HCT, Azor and Tribenzor) and allegations that such products caused sprue-like enteropathy and other severe gastro-intestinal symptoms.
  • The settlement program required, among other thresholds, that at least 97 percent of all eligible litigants and claimants decided to opt into the settlement and completed the required submissions.
  • Daiichi Sankyo continues to believe that the claims made in this litigation are without merit, and does not admit liability.
  • BENICAR HCT and TRIBENZOR are contraindicated in patients with anuria, and in patients with hypersensitivity to any component of BENICAR HCT or TRIBENZOR.